21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder

      research-article
      , JD, PhD, MPH 1 , 2 , , , MD, MS 2 , 3 , 4 , , PhD, MHS 2 , 3 , 4 , , PhD 2
      JAMA Network Open
      American Medical Association

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          What are the characteristics of US counties with high rates of opioid overdose mortality and low capacity to deliver medications for opioid use disorder?

          Findings

          In this cross-sectional study of data from 3142 US counties, counties in the South Atlantic, Mountain, and East North Central divisions had more than twice the odds of being at high risk for opioid overdose mortality and lacking in capacity to deliver medications for opioid use disorder. Higher density of primary care clinicians, a younger population, micropolitan status, and lower rates of unemployment were associated with lower risk of opioid overdose and lower risk of lacking in capacity to deliver medications for opioid use disorder.

          Meaning

          Strategies to address mortality from opioid overdose by increasing treatment for addiction should target urban counties in Appalachia, the Midwest, and the Mountain division and include efforts to increase primary care clinicians and employment opportunities.

          Abstract

          Importance

          Opioid overdose deaths in the United States continue to increase, reflecting a growing need to treat those with opioid use disorder (OUD). Little is known about counties with high rates of opioid overdose mortality but low availability of OUD treatment.

          Objective

          To identify characteristics of US counties with persistently high rates of opioid overdose mortality and low capacity to deliver OUD medications.

          Design, Setting, and Participants

          In this cross-sectional study of data from 3142 US counties from January 1, 2015, to December 31, 2017, rates of opioid overdose mortality were compared with availability in 2017 of OUD medication providers (24 851 buprenorphine-waivered clinicians [physicians, nurse practitioners, and physician assistants], 1517 opioid treatment programs [providing methadone], and 5222 health care professionals who could prescribe extended-release naltrexone). Statistical analysis was performed from April 20, 2018, to May 8, 2019.

          Exposures

          Demographic, workforce, lack of insurance, road density, urbanicity, opioid prescribing, and regional division county-level characteristics.

          Main Outcome and Measures

          The outcome variable, “opioid high-risk county,” was a binary indicator of a high (above national) rate of opioid overdose mortality with a low (below national) rate of provider availability to deliver OUD medication. Spatial logistic regression models were used to determine associations with being an opioid high-risk county.

          Results

          Of 3142 counties, 751 (23.9%) had high rates of opioid overdose mortality. A total of 1457 counties (46.4%), and 946 of 1328 rural counties (71.2%), lacked a publicly available OUD medication provider in 2017. In adjusted models, compared with the West North Central division, counties in the East North Central, Mountain, and South Atlantic divisions had increased odds of being opioid high-risk counties (East North Central: odds ratio [OR], 2.21; 95% CI, 1.19-4.12; Mountain: OR, 4.15; 95% CI, 1.34-12.89; and South Atlantic: OR, 2.99; 95% CI, 1.26-7.11). A 1% increase in unemployment was associated with increased odds (OR, 1.09; 95% CI, 1.03-1.15) of a county being an opioid high-risk county. Counties with an additional 10 primary care clinicians per 100 000 population had a reduced risk of being opioid high-risk counties (OR, 0.89; 95% CI, 0.85-0.93), as did counties that were micropolitan (vs metropolitan) (OR, 0.67; 95% CI, 0.50-0.90) and those that had an additional 1% of the population younger than 25 years (OR, 0.95; 95% CI, 0.92-0.98).

          Conclusions and Relevance

          Counties with low availability of OUD medication providers and high rates of opioid overdose mortality were less likely to be micropolitan and have lower primary care clinician density, but were more likely to be in the East North Central, South Atlantic, or Mountain division and have higher rates of unemployment. Strategies to increase medication treatment must account for these factors.

          Abstract

          This cross-sectional study examines characteristics of US counties with persistently high rates of opioid overdose mortality and low capacity to deliver medications for opioid use disorder.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence

          Cochrane Database of Systematic Reviews
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

            Methadone maintenance was the first widely used opioid replacement therapy to treat heroin dependence, and it remains the best-researched treatment for this problem. Despite the widespread use of methadone in maintenance treatment for opioid dependence in many countries, it is a controversial treatment whose effectiveness has been disputed. To evaluate the effects of methadone maintenance treatment (MMT) compared with treatments that did not involve opioid replacement therapy (i.e., detoxification, offer of drug-free rehabilitation, placebo medication, wait-list controls) for opioid dependence. We searched the following databases up to Dec 2008: the Cochrane Controlled Trials Register, EMBASE, PubMED, CINAHL, Current Contents, Psychlit, CORK [www. state.vt.su/adap/cork], Alcohol and Drug Council of Australia (ADCA) [www.adca.org.au], Australian Drug Foundation (ADF-VIC) [www.adf.org.au], Centre for Education and Information on Drugs and Alcohol (CEIDA) [www.ceida.net.au], Australian Bibliographic Network (ABN), and Library of Congress databases, available NIDA monographs and the College on Problems of Drug Dependence Inc. proceedings, the reference lists of all identified studies and published reviews; authors of identified RCTs were asked about other published or unpublished relevant RCTs. All randomised controlled clinical trials of methadone maintenance therapy compared with either placebo maintenance or other non-pharmacological therapy for the treatment of opioid dependence. Reviewers evaluated the papers separately and independently, rating methodological quality of sequence generation, concealment of allocation and bias. Data were extracted independently for meta-analysis and double-entered. Eleven studies met the criteria for inclusion in this review, all were randomised clinical trials, two were double-blind. There were a total number of 1969 participants. The sequence generation was inadequate in one study, adequate in five studies and unclear in the remaining studies. The allocation of concealment was adequate in three studies and unclear in the remaining studies. Methadone appeared statistically significantly more effective than non-pharmacological approaches in retaining patients in treatment and in the suppression of heroin use as measured by self report and urine/hair analysis (6 RCTs, RR = 0.66 95% CI 0.56-0.78), but not statistically different in criminal activity (3 RCTs, RR=0.39; 95%CI: 0.12-1.25) or mortality (4 RCTs, RR=0.48; 95%CI: 0.10-2.39). Methadone is an effective maintenance therapy intervention for the treatment of heroin dependence as it retains patients in treatment and decreases heroin use better than treatments that do not utilise opioid replacement therapy. It does not show a statistically significant superior effect on criminal activity or mortality.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Retention in medication-assisted treatment for opiate dependence: A systematic review.

              Retention in medication-assisted treatment among opiate-dependent patients is associated with better outcomes. This systematic review (55 articles, 2010-2014) found wide variability in retention rates (i.e., 19%-94% at 3-month, 46%-92% at 4-month, 3%-88% at 6-month, and 37%-91% at 12-month follow-ups in randomized controlled trials), and identified medication and behavioral therapy factors associated with retention. As expected, patients who received naltrexone or buprenorphine had better retention rates than patients who received a placebo or no medication. Consistent with prior research, methadone was associated with better retention than buprenorphine/naloxone. And, heroin-assisted treatment was associated with better retention than methadone among treatment-refractory patients. Only a single study examined retention in medication-assisted treatment for longer than 1 year, and studies of behavioral therapies may have lacked statistical power; thus, studies with longer-term follow-ups and larger samples are needed. Contingency management showed promise to increase retention, but other behavioral therapies to increase retention, such as supervision of medication consumption, or additional counseling, education, or support, failed to find differences between intervention and control conditions. Promising behavioral therapies to increase retention have yet to be identified.
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                28 June 2019
                June 2019
                28 June 2019
                : 2
                : 6
                : e196373
                Affiliations
                [1 ]Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor
                [2 ]Injury Prevention Center, Department of Emergency Medicine, University of Michigan Medical School, Ann Arbor
                [3 ]Department of Psychiatry, University of Michigan Medical School, Ann Arbor
                [4 ]Veterans Affairs Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan
                Author notes
                Article Information
                Accepted for Publication: May 11, 2019.
                Published: June 28, 2019. doi:10.1001/jamanetworkopen.2019.6373
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Haffajee RL et al. JAMA Network Open.
                Corresponding Author: Rebecca L. Haffajee, JD, PhD, MPH, Department of Health Management and Policy, University of Michigan School of Public Health, 1415 Washington Heights, Ann Arbor, MI 48109 ( haffajee@ 123456umich.edu ).
                Author Contributions: Drs Haffajee and Goldstick had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: All authors.
                Acquisition, analysis, or interpretation of data: Haffajee, Goldstick.
                Drafting of the manuscript: Haffajee, Goldstick.
                Critical revision of the manuscript for important intellectual content: All authors.
                Statistical analysis: Haffajee, Goldstick.
                Administrative, technical, or material support: Lin, Goldstick.
                Supervision: Haffajee, Goldstick.
                Conflict of Interest Disclosures: None reported.
                Funding/Support: Dr Haffajee was supported by grant KL2TR002241 from the National Center for Advancing Translational Sciences of the National Institutes of Health. Drs Haffajee, Bohnert, and Goldstick were supported by grant 3R49CE002099-05S1 from the Centers for Disease Control and Prevention for the University of Michigan Injury Prevention Center and grant U01CE002780 from the Centers for Disease Control and Prevention. Dr Lin was supported in part by a Career Development Award (CDA 18-008) from the US Department of Veterans Affairs Health Services Research & Development Service.
                Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Additional Contributions: Wanqi Ouyang, MS, and Lino Sanchez, MS, School for Environment & Sustainability and School of Natural Resources and Environment, University of Michigan, provided geospatial mapping assistance. Matthew Myers, MPH, Injury Prevention Center, Department of Emergency Medicine, University of Michigan Medical School, provided data management assistance. Ms Ouyang and Mr Sanchez were paid at an hourly rate for their work on this project. Mr Myers is a salaried employee who works for Dr Haffajee and provided assistance in that capacity for this study. We thank the University of Michigan Behavioral Health Workforce Center and the National Council for facilitating access to the list of prescribers of extended-release naltrexone from Alkermes Inc (free of charge).
                Article
                zoi190251
                10.1001/jamanetworkopen.2019.6373
                6604101
                31251376
                7ea1e7ad-92eb-4512-8660-1d082e4e0d18
                Copyright 2019 Haffajee RL et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 10 February 2019
                : 11 May 2019
                Categories
                Research
                Original Investigation
                Online Only
                Substance Use and Addiction

                Comments

                Comment on this article